Overview
Thymalin is a thymic peptide bioregulator developed by Vladimir Khavinson (the same researcher behind Epithalon) from bovine thymus extracts. It has been used in Russian clinical medicine since 1982 for immune system restoration, particularly in immunocompromised patients, the elderly, and post-surgical recovery. Khavinson's long-term studies suggest significant mortality reduction in elderly patients receiving thymalin.
Mechanism of action
Thymalin restores thymic function by modulating T-cell differentiation and maturation. It normalizes the ratio of CD4/CD8 T-cells, enhances natural killer (NK) cell activity, stimulates phagocytosis, and modulates cytokine production. In aging, the thymus involutes (shrinks) dramatically, reducing naive T-cell output — thymalin appears to partially reverse this immunosenescence. It also regulates the neuroendocrine-immune axis.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| immune restoration / anti-aging | intramuscular | 5–10 mg | daily | Standard Russian protocol: 5-10mg daily for 5-10 days. Repeat courses every 3-6 months. Often combined with Epithalon. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Khavinson's landmark study followed elderly patients for 6-15 years after treatment with thymalin + epithalon. The treatment group showed 1.6-1.8x lower mortality than controls. Thymalin normalized immunological markers, improved cardiovascular function, and reduced cancer incidence. Studies in post-surgical patients showed faster immune recovery and reduced infection rates. Approved in Russia for over 40 years with extensive clinical use. Limitations: most research is in Russian journals with limited Western replication.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Thymalin for synergistic effects.
Legal status
Approved in Russia as a pharmaceutical since 1982. Not FDA-approved. Available as a research peptide internationally. Part of Khavinson's peptide bioregulator system.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings.